Barclays analyst Etzer Darout raised the firm’s price target on BeOne Medicines (ONC) to $405 from $394 and keeps an Overweight rating on the shares post the Q4 report. The firm says the company’s data disclosures in 2026 will shed light into its longer-term pipeline growth opportunities.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONC:
- BeOne Medicines reports Q4 adjusted EPS $1.95, consensus $1.30
- BeOne Medicines sees 2026 revenue $6.2B-$6.4B, consensus $6.44B
- Beigene, Ltd. (ONC) Q4 Earnings Cheat Sheet
- BeOne Medicines price target raised to $394 from $385 at Barclays
- Zanubrutinib Update: What BeiGene’s BTK Intolerance Study Means for Oncology Investors